New Alliance Clinical Trial Aims to Improve Outcomes in Brain Tumors (IMAGE)
Caption
“IDH-mutant, grade 3 astrocytoma is a serious condition, and many of these tumors return even after aggressive, upfront treatment” said Ugonma Chukwueke, MD, MPH, Alliance study chair and a neuro-oncologist at the Dana-Farber Cancer Institute in Boston. “By adding a newer, targeted therapy aimed at the underlying IDH mutation, this study could help in identifying a more effective option for people with this type of brain cancer, which has been a long-standing unmet need in our field. If successful, vorasidenib could become the first widely used IDH‑targeted medicine added to standard care for this patient population.”
Credit
Dana-Farber Cancer Center
Usage Restrictions
none
License
Original content